From trauma and spine surgeries, to hip and knee arthroplasties, there is an enormous need for biocompatible grafts with osteoconductive properties. While autografts have historically been the gold standard, their use is subject to availability, cost constraints, and safety concerns related to a higher morbidity risk. Leader Biomedical’s Orthobiologics portfolio offers high-quality allografts and synthetic grafts, both of which eliminate the restrictions associated with autografts.
All Leader Biomedical allografts are processed with our proprietary eCOO® Technology using supercritical carbon dioxide to clean, sterilise, and impregnate human and animal-derived bone and tissue. Our OssGro® line of synthetic grafts are produced with MBCP™ Technology, a proprietary method composed of 60% HA and 40% βTCP.